Ryan Baron

Ryan Baron

Auto-generated profile, based on publicly available information

Ryan Baron

Radiology, University of Pennsylvania, Philadelphia, PA, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
HHHooman Hamedani
Hooman Hamedani
KMKevin Ma
Kevin Ma
DDDavid DiBardino
David DiBardino
RBRyan Baron
Ryan Baron
SKStephen Kadlecek
Stephen Kadlecek
RRRahim R. Rizi
Rahim R. Rizi

14 July 2021 in Academic Radiology
Verified
Journal Article
Closed access
RBRyan Baron
Ryan Baron
SKStephen Kadlecek
Stephen Kadlecek
LLLuis Loza
Luis Loza
YXYi Xin
Yi Xin
FAFaraz Amzajerdian
Faraz Amzajerdian
RRRahim Rizi
Rahim Rizi

30 April 2026 in Hepatology
Verified
Journal Article
Closed access
DBDaniel J. Boehmler
Daniel J. Boehmler
RBRyan J. Baron
Ryan J. Baron
JBJennifer A. Brain
Jennifer A. Brain
AIAriful Islam
Ariful Islam
YKYohan Kim
Yohan Kim
TGTerence Gade
Terence Gade
Background and Aims: Metabolic inhibitors have demonstrated limited efficacy for cancer therapy due to metabolic plasticity and systemic toxicity. Locoregional therapies (LRT), such as transarterial embolization (TAE) or transarterial chemoembolization (TACE), generate ischemic stress that reprograms the tumor microenvironment (TME) toward glycolytic dependency, creating an opportunity to sensitize hepatocellular carcinoma (HCC) to metabolic inhibition. This study investigated whether pharmacologic inhibition of lactate dehydrogenase (LDH) with NCATS-SM1441 could exploit TAE-induced metabolic vulnerabilities to improve therapeutic efficacy in HCC. Approach and Results: Human HCC cell lines were exposed to replete or ischemic (TAE-like) conditions and treated with the LDH inhibitor NCATS-SM1441. Glucose/lactate flux, adenosine triphosphate (ATP) levels, and viability were assessed. In vivo, a diethylnitrosamine (DEN)-induced rat HCC model was treated with intra-arterial NCATS-SM1441, TAE, or their combination. Drug distribution, tumor metabolism, necrosis, and survival were analyzed using mass spectrometry imaging, histopathology, T2-weighted magnetic resonance imaging (MRI), and survival metrics. Ischemic conditions induced LDHA expression and glycolytic flux, enhancing susceptibility to LDH inhibition. The combination of intra-arterial NCATS-SM1441 before embolization increased intratumoral drug accumulation, reduced systemic exposure, and synergized with TAE to suppress lactate production, promote tumor necrosis, and significantly extend local progression-free survival. Conclusions: TAE conditions the TME to create a therapeutically targetable glycolytic dependency. Combining TAE with LDH inhibition overcomes key limitations of metabolic inhibitors as monotherapies, enhancing local control and survival with minimal systemic toxicity, supporting integration of metabolism-targeted agents with LRT for unresectable HCC.

1 May 2023
Verified
Conference Paper
Closed access
MIM.K. Ismail
M.K. Ismail
YXY. Xin
Y. Xin
HHH. Hamedani
H. Hamedani
FAF. Amzajerdian
F. Amzajerdian
RBR. Baron
R. Baron
RRR.R. Rizi
R.R. Rizi

1 May 2023
Verified
Conference Paper
Closed access
MIM.K. Ismail
M.K. Ismail
HHH. Hamedani
H. Hamedani
RBR. Baron
R. Baron
FAF. Amzajerdian
F. Amzajerdian
LLL. Loza
L. Loza
RRR.R. Rizi
R.R. Rizi

1 May 2023
Verified
Conference Paper
Closed access
LLL. Loza
L. Loza
ZSZachary Schug
Zachary Schug
FAF. Amzajerdian
F. Amzajerdian
HHH. Hamedani
H. Hamedani
RBR. Baron
R. Baron
RRR.R. Rizi
R.R. Rizi